Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.

Gregory W SchwartzBryan ManningYeqiao ZhouPriya VeluAshkan BigdeliRachel AstlesAnne W LehmanJennifer J D MorrissetteAlexander E PerlMingyao LiMartin CarrollRobert B Faryabi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

These results underscore the importance of structural discernment of complex somatic mutations such as ITDs in progressing toward personalized treatment of AML patients, and enable researchers and clinicians to unravel ITD complexity using the provided software.See related commentary by Gallipoli and Huntly, p. 460.

Keyphrases

acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
newly diagnosed
prognostic factors
palliative care
gene expression
metabolic syndrome
patient reported outcomes
adipose tissue
tyrosine kinase
insulin resistance
smoking cessation
replacement therapy
patient reported